Recent updates in salivary gland tumors of the lung

Roden, Anja C.

doi:10.1053/j.semdp.2021.03.001

Cited by 15 publications

(20 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence rate of primary adenoid cystic carcinoma (PACC) is lower than the rate of PMEC in adults [ 7 ]. However, no remarkable difference in the clinical manifestation between PMEC and PACC exists [ 3 ].…”

Section: Differential Diagnosismentioning

confidence: 99%

“…As for the results of the immunohistochemical examination, PACC expresses CD117(c-kit protein) and myoepithelial markers, including pancytokeratin, p63, and CK7. MYB-NFIB fusion carcinogens generated by tumor-specific t (6; 9) (q22-23; p23-24) translocation are considered to be specific to PACC [ 7 , 55 ].…”

Section: Differential Diagnosismentioning

confidence: 99%

“…In 1952, Smetana et al [1] frst reported pulmonary mucoepidermoid carcinoma (PMEC) as a scarce malignant neoplasm in the lungs that accounted for 0.1-0.2% of all lung malignancies in adults [2][3][4][5][6]. PMEC, the most common primary salivary gland carcinoma (SGC) in the lung, originates from the minor salivary glands in the submucosa of large airways [7]. PMEC occurs in any age group; some studies reported its occurrence primarily in younger adults under 50 [8].…”

Section: Introductionmentioning

confidence: 99%

“…The most common genetic change is t (11; 19) ( q 21; p 13), which generates the fusion protein MECT1-MAML2. Since MECT1-MAML2 fusion was demonstrated to be present in more than 66% of all PMEC cases [ 8 , 10 , 11 ], it was proposed to drive PMEC progress [ 7 ]. Several other gene mutations were also reported.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pulmonary Salivary Gland Tumor, Mucoepidermoid Carcinoma: A Literature Review

Gong

Zhu

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Pulmonary mucoepidermoid carcinoma (PMEC) is the most common malignant salivary gland tumor in the lungs and accounts for 0.1-0.2% of all lung malignancies in adults. It has no specific epidemiological or clinical characteristics. Correct diagnosis requires the combined examinations of images, laboratories, pathology, and immunohistochemistry (IHC) as well as molecular characteristics. PMEC tumors are characterized by squamous, intermediate, and mucus-secreting cells. Currently, histological appearance, mitotic frequency, cellular atypia, and necrocytosis allow the classification of PMEC into low grade or high grade. Molecular changes are crucial to pathological diagnosis. The driver of PMEC seems to be the fusion protein MECT1-MAML2 that is generated from a genetic mutation in t (11; 19) (q21; p13), while other gene mutations are also reported. However, no treatment of PMEC exists so far; surgical excision is still the primary treatment, while the efficacies of chemotherapy or radiotherapy are undefined. Tyrosine kinase inhibitor (TKI) therapy and immunotherapy showed to have significant therapeutic effects but require more investigation and better understanding. This review focuses on the clinical characteristics, imaging and pathologic features, immunohistochemical examination, mutation analysis, differential diagnosis, prognosis, and treatment of PMEC.

show abstract

Section: Differential Diagnosismentioning

confidence: 99%

Section: Differential Diagnosismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pulmonary Salivary Gland Tumor, Mucoepidermoid Carcinoma: A Literature Review

Gong

Zhu

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Molecular tests demonstrating MAML2 rearrangement in difficult cases are diagnostic. 34,37 To avoid the misinterpretation of SP, it is important to recognise that the tumour is usually located in the main or lobar bronchus, has characteristic histopathological features of exophytic proliferation of papillary stratified squamous epithelium and is contiguous with endophytic salivary ductal proliferation underneath. This presents evidence of an intraductal nature, as confirmed by the presence of basal cells.…”

Section: Diagnostic Issues and Differential Diagnosismentioning

confidence: 99%

Pulmonary sialadenoma papilliferum and its mimics: what you need to know

Gao

Sun

2022

Histopathology

View full text Add to dashboard Cite

Pumonary salivary gland‐type tumours (SGT) represent a small but distinct group of primary lung neoplasms. These types of tumours originate from the submucosal bronchial glands of the tracheobronchial tree. Pulmonary SGTs differ greatly in the incidence of individual tumours from salivary gland tumours of the head and neck. Additionally, the vast majority of pulmonary SGT are malignant. Recently, pathological diagnosis has significantly improved with the application of molecular diagnostic technologies. However, the current knowledge of benign SGTs is limited; moreover, tumour diversity and overlapping morphological features of SGT represent diagnostic challenges such as correct tumour categorisation and their accurate differentiation from malignant lesions. Compounding this inherent difficulty has been the recent introduction of new variants, including sialadenoma papilliferum (SP). Pulmonary SP is very rare, with limited reports available, and most of the initial diagnoses rendered so far were incorrect, resulting in inappropriate treatment. Several cases of SP have recently been reported. This review will serve to update practicing pathologists on the morphology, immunophenotype and molecular characteristics of SP and its mimics.

show abstract